{"id":64062,"date":"2026-04-27T21:13:55","date_gmt":"2026-04-27T13:13:55","guid":{"rendered":"https:\/\/flcube.com\/?p=64062"},"modified":"2026-04-27T21:13:57","modified_gmt":"2026-04-27T13:13:57","slug":"cspc-pharmaceutical-receives-fda-clearance-to-launch-first-in-class-kat6-inhibitor-syh2095-clinical-trial-for-advanced-cancers","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64062","title":{"rendered":"CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers"},"content":{"rendered":"\n

CSPC Pharmaceutical Group Ltd<\/strong> (HKG: 1093<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has granted clearance to initiate a clinical trial of SYH2095<\/strong>, a Category 1 innovative chemical entity<\/strong> and first-in-class lysine acetyltransferase 6 (KAT6) inhibitor<\/strong>, for the treatment of advanced malignancies<\/strong>.<\/p>\n\n\n\n

SYH2095 represents a novel epigenetic anticancer therapy<\/strong> that selectively targets chromatin regulation by inhibiting histone lysine acetylation<\/strong>, thereby blocking open chromatin formation and modulating key oncogenic pathways\u2014including cell cycle progression, estrogen receptor expression, and cellular senescence<\/strong>.<\/p>\n\n\n\n

Drug Mechanism & Preclinical Profile<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Target<\/strong><\/td>KAT6 (lysine acetyltransferase 6) \u2013 epigenetic regulator overexpressed in multiple cancers<\/td><\/tr>
Mechanism<\/strong><\/td>Inhibits histone H3 lysine acetylation \u2192 suppresses chromatin accessibility \u2192 arrests tumor cell proliferation<\/td><\/tr>
Preclinical Efficacy<\/strong><\/td>Potent and selective KAT6 inhibition<\/strong>; significant tumor growth suppression in xenograft models<\/td><\/tr>
Pharmacokinetics<\/strong><\/td>Favorable oral bioavailability, half-life, and tissue distribution<\/td><\/tr>
Safety<\/strong><\/td>Clean off-target profile; no severe toxicity observed in GLP toxicology studies<\/td><\/tr>
Innovation Status<\/strong><\/td>Category 1 New Drug<\/strong> (China NMPA classification); wholly owned intellectual property<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Significance for CSPC<\/h2>\n\n\n\n